Rules of Automation

Koppal, Tanuja
August 2005
Drug Discovery & Development;Aug2005, Vol. 8 Issue 8, p9
Focuses on the significance of automation in pharmaceutical processes. Role of automation in improving the quality of the products while reducing costs; Ability of automation in improving speed, increased accuracy, and heightened process efficiencies; Infiltration of automation in areas including discovery, manufacturing, and clinical trials.


Related Articles

  • The Do's and Don'ts ol Automated Screening. McGee, Patrick // Drug Discovery & Development;Aug2005, Vol. 8 Issue 8, p22 

    Provides guidelines on how to avoid the common pitfalls that arise in the process of automating compound screening. Importance of identifying key success criteria before implementing the project; Need to discuss the plan with end users; Advice for companies to build their own system;...

  • Developments in Tooling Inspections and Technology. Caruso, Robert // Pharmaceutical Technology;May2008 Supplement, Vol. 32, ps30 

    The article focuses on the development of computer software and equipment needed in-process tool inspections in tablet manufacturing. It relates that tablets in-process inspections must be limited to only two dimensions including punch working length dimension and cup depth which have the...

  • Developing New Drugs in 1000 Days. Gugliotti, Jan // Applied Clinical Trials;Aug2002, Vol. 11 Issue 8, p44 

    Explores the implications of the speed and capacity in clinical trials of the U.S. competitive pharmaceutical industry for drug development. Innovation-driven improvement in clinical development time; New drug application approval time; Good laboratory practice. INSETS:...

  • Overhauling clinical trials. Scott, Christopher Thomas; Baker, Monya // Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p287 

    The article examines the designs of clinical trials that adapt midstream which are billed as a cure for challenges in drug development. Drug companies do not apply adaptive designs to individual projects but spread them across their portfolios. The United States Food and Drug Administration...

  • Double Dip: Doctors Paid to Advise, Promote Drug Companies That Fund Their Research. Ornstein, Charles; Jones, Ryann Grochowski // Pro Publica;3/1/2014, p12 

    The article focuses on the stronger relationship between pharmaceutical companies and physicians in the U.S. It notes the willingness of pharmaceutical companies to pay for physicians who conduct their clinical trials and give speeches on behalf of their drugs. It also mentions the criticism of...

  • SECTION INDEX.  // Monthly Prescribing Reference;Oct2016, Vol. 32 Issue 10, pA24 

    The section index in the journal which features different disorders and their treatments is presented.

  • Drug companies must report clinical trial results, even when they won't lead to a product.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p157 

    The article reports on the need for drug companies performing clinical trials to disclose the results of their research, even if they do not longer pursue product development.

  • No end to European evolution? O'Donnell, Peter // Applied Clinical Trials;Dec2003, Vol. 12 Issue 12, p53 

    Discusses the efforts of the European Union to update its pharmaceutical rules in 2003. Outcome of the major review conducted by the European Agency for the Evaluation of Medicinal Products; Goal of implementing the rules by May 2004; Details of the proposed legislative changes in the extensive...

  • R&D UPDATE: Lung Cancer.  // PharmaWatch: Cancer;February 2003, Vol. 2 Issue 2, p5 

    Reports on developments of drugs for lung cancer treatment in the U.S. as of January 2003. Delay of the decision of the U.S. Food and Drug Administration (FDA) regarding the priority review of the new Iressa drug requested by AstraZeneca PLC; Announcement of the result of the phase I/II...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics